Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients. More Details
Good value with reasonable growth potential.
Share Price & News
How has Fagron's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: Insufficient data to determine FAGRB's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine FAGRB's volatility change over the past year.
7 Day Return
1 Year Return
Return vs Industry: FAGRB underperformed the UK Healthcare industry which returned 52.5% over the past year.
Return vs Market: FAGRB underperformed the UK Market which returned 26.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Fagron's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Fagron undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: FAGRB (€19.04) is trading below our estimate of fair value (€37.28)
Significantly Below Fair Value: FAGRB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: FAGRB is good value based on its PE Ratio (22.8x) compared to the GB Healthcare industry average (32.6x).
PE vs Market: FAGRB is good value based on its PE Ratio (22.8x) compared to the UK market (26.4x).
Price to Earnings Growth Ratio
PEG Ratio: FAGRB is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: FAGRB is overvalued based on its PB Ratio (5.4x) compared to the GB Healthcare industry average (2.1x).
How is Fagron forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FAGRB's forecast earnings growth (17.6% per year) is above the savings rate (0.9%).
Earnings vs Market: FAGRB's earnings (17.6% per year) are forecast to grow faster than the UK market (17.5% per year).
High Growth Earnings: FAGRB's earnings are forecast to grow, but not significantly.
Revenue vs Market: FAGRB's revenue (8.3% per year) is forecast to grow faster than the UK market (5.3% per year).
High Growth Revenue: FAGRB's revenue (8.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FAGRB's Return on Equity is forecast to be high in 3 years time (22.4%)
How has Fagron performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FAGRB has high quality earnings.
Growing Profit Margin: FAGRB's current net profit margins (10.7%) are higher than last year (10.3%).
Past Earnings Growth Analysis
Earnings Trend: FAGRB has become profitable over the past 5 years, growing earnings by 60.4% per year.
Accelerating Growth: FAGRB's earnings growth over the past year (7.9%) is below its 5-year average (60.4% per year).
Earnings vs Industry: FAGRB earnings growth over the past year (7.9%) underperformed the Healthcare industry 15.3%.
Return on Equity
High ROE: Whilst FAGRB's Return on Equity (23.29%) is high, this metric is skewed due to their high level of debt.
How is Fagron's financial position?
Financial Position Analysis
Short Term Liabilities: FAGRB's short term assets (€221.9M) exceed its short term liabilities (€200.3M).
Long Term Liabilities: FAGRB's short term assets (€221.9M) do not cover its long term liabilities (€294.8M).
Debt to Equity History and Analysis
Debt Level: FAGRB's debt to equity ratio (124.8%) is considered high.
Reducing Debt: FAGRB had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: FAGRB's debt is well covered by operating cash flow (28.9%).
Interest Coverage: FAGRB's interest payments on its debt are well covered by EBIT (8.8x coverage).
What is Fagron current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: FAGRB's dividend (0.96%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.35%).
High Dividend: FAGRB's dividend (0.96%) is low compared to the top 25% of dividend payers in the UK market (4.03%).
Stability and Growth of Payments
Stable Dividend: FAGRB's dividend payments have been volatile in the past 10 years.
Growing Dividend: FAGRB's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (21.8%), FAGRB's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: FAGRB's dividends in 3 years are forecast to be well covered by earnings (19.4% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rafael Padilla (42 yo)
Mr. Rafael Padilla has been Chief Executive Officer at Fagron NV since November 27, 2017 and served as its Area General Manager of South America and Southern Europe since October 25, 2016. Mr. Padilla serv...
CEO Compensation Analysis
Compensation vs Market: Rafael's total compensation ($USD933.40K) is below average for companies of similar size in the UK market ($USD1.36M).
Compensation vs Earnings: Rafael's compensation has been consistent with company performance over the past year.
Experienced Management: FAGRB's management team is considered experienced (3.3 years average tenure).
Experienced Board: FAGRB's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Fagron NV's company bio, employee growth, exchange listings and data sources
- Name: Fagron NV
- Ticker: FAGRB
- Exchange: BATS-CHIXE
- Founded: 1990
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: €1.364b
- Shares outstanding: 72.37m
- Website: https://www.fagron.com
Number of Employees
- Fagron NV
- Venecoweg 20A
- East Flanders
Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients. It prepares personalized ready-to-use medication in its sterile a...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/10 02:29|
|End of Day Share Price||2021/04/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.